ClinicalTrials.gg
CompletedNCT04557280Updated Jul 3, 2025

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

A Phase 1 interventional study of Selatogrel and Selatogrel in Healthy Subjects, sponsored by Viatris Innovation GmbH. Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

The main purpose is to study the pharmacokinetics of selatogrel (ACT-246475) using different administration modes and formulations. The clinical pharmacology data will be used to support demonstration of bioequivalence and interchangeability of the different formulations.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the participant prior to any study-mandated procedure.
  • Healthy male or female participant aged between 18 and 59 years (inclusive) at screening.
  • of 18.0 to 31.9 kg/m2 (inclusive) at screening and a minimum weight of 50.0 kg at screening and on Day -1.
  • Systolic blood pressure 100 to 140 mmHg, diastolic blood pressure 50 to 90 mmHg, and pulse rate 45 to 100 bpm (inclusive), measured on the left arm, after 5 minutes in the supine position at screening and Day-1.
  • 12-lead (ECG) without abnormalities, measured after 5 min in the supine position at screening and on Day-1.
  • Clinical laboratory values are within the standard normal ranges or determined to be clinically insignificant in the opinion of the investigator at screening and on Day -1.
  • Women must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline (i.e., Day -1 of the first period). Women of must consistently and correctly use (from screening, during the entire study, and for at least 30 days after last study treatment injection) an acceptable effective method of , be sexually inactive, or have a vasectomized partner. If a hormonal contraceptive is used, it must be initiated at least 1 month before first treatment administration.
  • Women of non-childbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating woman.
  • Previous exposure to selatogrel (ACT-246475).
  • Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs, P2Y12 receptor antagonists, or any medication with blood-thinning activity (i.e., injectable or oral anticoagulants) within 3 weeks prior to study treatment administration.
  • Treatment with another small molecule drug within 30 days or 5 x terminal half-lives ([t½], whichever is longer) or with an investigational biologic drug within 90 days prior to screening.
  • Known to P2Y12 receptor antagonists or to used in any of the formulations.
  • History or clinical evidence of alcoholism or drug abuse within 3 years prior to screening.
  • History of major medical or surgical disorders, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Family or personal history of prolonged bleeding (e.g., after surgical intervention) or bleeding disorders (e.g., thrombocytopenia, clotting disturbances), intracranial vascular diseases, stroke, , reasonable suspicion of vascular malformations, peptic ulcers.
  • count less than 120 x10\^9 per litre at screening and on Day-1.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A: liquid formulation via auto-injector

    Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an auto-injector forming an integral ready-to-use single-dose drug delivery system.

    Combination Product: Selatogrel

  • Experimental
    Treatment B: liquid formulation via syringe

    Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe.

    Combination Product: Selatogrel

  • Experimental
    Treatment C: lyophilizate-based formulation via syringe

    Selatogrel will be administered as a reconstituted lyophilizate-based formulation for injection.

    Drug: Selatogrel

Interventions

  • Combination productSelatogrel

    A single subcutaneous injection of 16 mg.

    Also known as: ACT-246475

  • A single subcutaneous injection of 16 mg.

    Also known as: ACT-246475

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC0-t) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  2. The area under the plasma concentration-time curve from zero to infinity (AUC0-inf) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  3. The maximum plasma concentration (Cmax) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  4. Time to reach Cmax (tmax)

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  5. Terminal half-life (t½) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

Secondary outcomes

  1. Change from baseline in systolic and diastolic supine blood pressure

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  2. Change from baseline in pulse rate

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  3. Change from baseline in body weight

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  4. Change from baseline in the electric activity of the heart (12-lead electrocardiogram)

    Changes in the PQ-, PR-, RR-, and QRS-interval will be measured. In addition, the QTc-interval corrected for heart rate using Bazett's (QTcB) and Fridericia's formula (QTcF) will be assessed.

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  5. Change from baseline in coagulation laboratory tests

    Blood samples will be taken under fasted conditions and the following tested: prothrombin time and international normalized ratio, as well as activated partial thromboplastin time.

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  6. Change from baseline in clinical chemistry tests

    Blood samples will be taken under fasted conditions and the following tested: aspartate aminotransferase / alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, total and direct bilirubin, lactate dehydrogenase; creatinine, urea; urate; glucose; cholesterol, triglycerides; sodium, potassium, chloride, calcium; protein, albumin.

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  7. Change from baseline in clinical hematology tests

    Blood samples will be taken under fasted conditions and the following tested: hemoglobin, hematocrit, erythrocytes, leukocytes; as well as a differential blood count (including basophils, eosinophils, neutrophils, lymphocytes and monocytes); and platelets.

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

07

Study locations

1 site
  • Altasciences Clinical Kansas, Inc
    Overland Park, Kansas 66212, United States
08

References and documents

Publications

  • Zenklusen I, Hsin CH, Schilling U, Kankam M, Krause A, Ufer M, Dingemanse J. Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects. Clin Pharmacokinet. 2022 May;61(5):687-695. doi: 10.1007/s40262-021-01097-9. Epub 2021 Dec 28. PubMed 34961905 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2020
First posted
Sep 21, 2020
StartActual
Nov 6, 2020
Primary completionActual
Dec 19, 2020
CompletionActual
Dec 19, 2020
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04557280
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Nov 6, 2020
Primary completion
Dec 19, 2020
Completion
Dec 19, 2020
Last update
Jul 3, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selatogrel

Start the discussion